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Objectives: The aim of this prospective study was to investigate the implementation of an enhanced
recovery after surgery (ERAS) programme following pancreaticoduodenectomy (PD).
Methods: Patients undergoing PD were managed according to an ERAS protocol. Outcome measures
included postoperative mortality, morbidity, hospitalization and 30-day readmission rate. Key protocol
targets were: nasogastric tube (NGT) removal [postoperative day (PoD) 1]; resumption of oral fluids
(PoD 1); urinary catheter removal (PoD 3); high-dependency unit (HDU) discharge (PoD 3); tolerating diet
(PoD 4); drain removal (PoD 5), and hospital discharge (PoD 6).
Results: Data were collected for 50 patients (24 male; median age 67 years). Rates of mortality,
morbidity and readmission were 4%, 46% and 4%, respectively. The median length of postoperative
hospitalization was 10 days. The proportions of patients achieving key targets were: 78% for NGT
removal; 82% for resumption of oral fluids; 48% for urinary catheter removal; 82% for HDU discharge;
86% for tolerating diet; 84% for meeting mobility targets, and 72% for drain removal. One patient was
discharged by PoD 6, eight patients by PoD 7, 15 patients by PoD 8 and 26 patients (52%) by PoD 10.
Discharge was delayed in 16 patients for social or transport-related reasons.
Conclusions: The ERAS protocol was implemented safely. Achieving certain targets was challenging.
Non-medical causes remain a significant factor in delayed discharge following PD.
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Introduction
An ‘enhanced recovery after surgery’ (ERAS) programme repre-
sents an interdisciplinary model, designed with the intention
of safely hastening postoperative recovery by easing the stress
response. Inevitably, postoperative complications impede recov-
ery. However, several factors other than morbidity delay recupera-
tion in postoperative patients, namely: pain; gut dysfunction, and
immobility. Rehabilitation pathways apply evidence-based prin-
ciples of care, focusing on the optimization of postoperative anal-
gesia, early feeding, and ambulation to reduce stress and organ
dysfunction.1–3 Such fast-track programmes have proven very suc-
cessful following various major gastrointestinal (GI) operations,
including colorectal and liver resections.4–7 These ERAS pathways
can accelerate recovery, decrease morbidity and reduce hospital
length of stay (LoS) without compromising patient safety, whilst
utilizing health resources in an optimal way.8,9
Pancreatic cancer is the fourth leading cause of cancer death in
men, the fifth in women and the second most common cause of
death among all GI malignancies.10–12 Pancreaticoduodenectomy
(PD) remains the mainstay of surgical treatment for periampul-
lary malignancy and offers the only chance of longterm survival.
Median survival following surgery performed with curative intent
for pancreatic adenocarcinoma is reported to be 11–18 months
and 5-year survival lies in the range of 10–21%.13–15 Postoperative
mortality risk is typically <5% in high-volume institutions,16–24
but morbidity remains high at 30–40%.24–33
Relatively few studies have assessed the implementation of
an ERAS programme following PD.19,20,34–39 Some studies have
reported the feasibility and effect on reducing postoperative LoS
and hospital costs.20,34,35 Other works have demonstrated low
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morbidity, mortality and readmission rates following the imple-
mentation of fast-track programmes.19,36 However, to date, none
of this has been assessed in a UK context.
The principal aim of this pilot study was to evaluate the safety
and efficacy of implementing an ERAS programme for patients
undergoing PD in a high-volume UK institution.
Materials and methods
From February 2010 to July 2011, 50 consecutive patients under-
going PD were managed according to an ERAS protocol. Data
were collected prospectively using a standard proforma and
recorded in an electronic database. This facilitated the daily
recording of parameters central to the implementation of an
ERAS protocol (e.g. drain volumes, drain fluid amylase levels,
commencement of oral feeding, mobilization, catheter removal).
An ERAS protocol was designed by the multidisciplinary
hepatopancreatobiliary (HPB) team subsequent to a review of
previously published reports in the literature and the gauging of
what might be achievable in a specialist HPB unit within the UK
(Table 1). Targets were established for the management of patients
from the evening of the day of surgery until discharge. The initial
target for discharge was postoperative day (PoD) 6 following PD.
The protocol utilized defined criteria for certain elements of post-
operative management, such as epidural analgesia, nasogastric
tube (NGT) removal, high-dependency unit (HDU) discharge,
intra-abdominal drain removal, and hospital discharge (Table 2).
Epidural management is summarized in Fig. 1. The ERAS proto-
col also included targets for mobilization, i.v. fluid reduction and
withdrawal, introduction of oral fluid/diet and urinary catheter
removal.
Patients received effective analgesia from the day of surgery in
the form of epidural or patient-controlled analgesia (PCA). They
followed a programme of daily mobilization, which began with
getting up to sit on the evening of the day of surgery and pro-
gressed to walking for 20 min on PoD 4. The NGT was removed
on PoD 1 if the drainage volume was <500 ml. Clear fluids were
allowed from PoD 1 and solid food was allowed from PoD 4.
Intravenous fluids were reduced to 1 l per day if oral intake was
>500 ml and stopped if oral intake was >1 l. Intra-abdominal
drains were ‘cut and bagged’ on PoD 2 to improve mobility. The
target was to discharge patients from the HDU by PoD 3. On PoD
5, samples of drain fluid were sent to the laboratory for analysis of
amylase levels. Drains were removed if the amylase level was
<300 U/l and drain output was <100 ml. The aim was to discharge
patients from hospital on PoD 6.
Postoperatively, patients were provided with thromboprophy-
laxis in the form of subcutaneous heparin (5000 U, twice daily) or
subcutaneous low-molecular-weight heparin (dalteparin sodium,
2500 U, once daily, or enoxaparin sodium, 2000 U, once daily). A
subcutaneous somatostatin analogue (octreotide, 100–200 mg,
three times daily) was prescribed at the discretion of the respon-
sible surgeon. All patients were prescribed an anti-emetic and acid
suppression was provided in the form of either i.v. H2-receptor
antagonist (ranitidine, 50 mg, three times daily) or an oral
proton-pump inhibitor (lansoprazole, 30 mg, once daily).
Table 1 Protocol for the enhanced recovery after surgery (ERAS) programme
PoD Targets for postoperative
management
0 Postoperative analgesia: epidural or PCA (refer to epidural management criteria)
Mobilization: up to sit
1 Postoperative analgesia: oral analgesia following NGT removal
NGT: removed if drainage volume <500 ml (refer to NGT removal criteria)
Fluid balance: allow free clear fluids; reduce i.v. fluids to 1 l/day if oral intake is >500 ml
Mobilization: up to sit for 1 h
2 Intra-abdominal drains: cut and bag drains to improve mobility
Mobilization: up to sit for 2 h
3 Postoperative analgesia: stop epidural
Urinary catheter: remove urinary catheter when epidural is stopped
Fluid balance: stop i.v. fluids if oral intake is >1 l
HDU: consider discharge to ward (refer to HDU discharge criteria)
Mobilization: up to sit for 2 h and short walk around bed
4 Nutrition: solid food intake
Mobilization: walking for 20 min
5 Intra-abdominal drains: fluid amylase levels of drains sent to laboratory; remove drain if amylase is <300 U/l and drain output is <100 ml
(refer to drain removal criteria)
6 Hospital discharge: consider discharge if hospital discharge criteria are met
PoD, postoperative day; PCA, patient-controlled analgesia; NGT, nasogastric tube; HDU, high-dependency unit.
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Table 2 Outline of postoperative management targets in the protocol for the enhanced recovery after surgery (ERAS) programme
Criteria
Epidural management Refer to Figure 1
NGT removal • If 24-h postoperative NGT drainage is <500 ml, NGT can be safely removed and clear oral fluids initiated
• EXCLUSION If significant preoperative gastric outlet obstruction was present, seek consultant surgeon opinion prior
to removal of NGT
• If persistent vomiting is present thereafter, consider replacement of NGT
DGE = NGT remains in place for >3 days or has been reinserted for persistent vomiting after PoD 3 or inability to
tolerate a solid diet by PoD 7
HDU discharge Respiratory
• Requiring <40% oxygen
• Respiratory rate <20 and >10 breaths/min
• SpO2 >95% (may be lower in patients with COPD)
• Good cough reflex and cooperation with physiotherapy
Cardiovascular
• Not requiring ECG or CVP measurement (although CVP line may be in place)
• Not requiring an arterial line, inotropes or bolus administration of fluid
• Able to mobilize out of bed without need for inotropes
Renal
• Stable renal function, passing 25 ml/h urine
• Urea and creatinine not increasing (confirmed on morning of transfer)
Neurological
• Patient alert and obeying commands
Analgesia
• Pain is well controlled on current method of analgesia
Blood tests
• Stable or improving (confirmed on morning of transfer)
General
• Able to mobilize out of bed
Intra-abdominal
drain removal
• Monitor daily drain output volumes
• PoD 2: drains cut and bagged to facilitate mobilization
• PoD 5: assessment of drain volume nature and amylase content
Drains removed if:
1 Drain volume is <100 ml
2 Fluid is clear in colour
3 Amylase is <300 IU/l
NB If drain removal criteria are not met, further drain management will be at the discretion of the consultant
Hospital
discharge
Patients must achieve all of the following:
• Adequate pain control on oral analgesia
• Ability to eat and drink with no requirement for i.v. fluids in previous 24 h
• Independent mobility (can mobilize independently to toilet)
• Ability to perform activities of daily living (washing, dressing) without help from nursing staff
• Return of blood tests to normal range
• Willingness to go home
NGT, nasogastric tube; HDU, high-dependency unit; DGE, delayed gastric emptying; PoD, postoperative day; SpO2, saturation of peripheral oxygen;
COPD chronic obstructive pulmonary disease; ECG, electrocardiogram; CVP, central venous pressure.
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Pain score moderate/severe or
≥ 4
Check epidural catheter system intact and
running
Catheter in place 
• Top up epidural as prescribed on
epidural chart and re-assess
Pain absent/mild or < 4
• Continue to score
pain 
Pain score still
moderate/severe or ≥ 4
• Give second epidural top-up and
re-assess
Pain absent/mild or < 4
• Continue to score
pain
Pain score still
moderate/severe or ≥ 4
• Give third epidural top-up and
re-assess
Pain absent/mild or < 4
• Continue to score
pain
Pain score still moderate/severe
or ≥ 4
• Start PCA
• Remove epidural catheter
when INR < 1.5  
Pain score still moderate/severe
or ≥ 4 despite PCA, or
patient oversedated with PCA
• Consider ketamine
infusion
Catheter dislodged and INR > 1.5
or cannot be replaced for other
reasons
 
• Start morphine PCA (set bolus
to 1 mg)
Epidural should be discontinued on PoD 3
and PCA initiated
Figure 1 Epidural management. PCA, patient-controlled analgesia; INR, international normalized ratio; PoD, postoperative day
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Measures of outcome
Data were collected on: demographics; preoperative bilirubin
level; indication for PD; pathology of resected specimen; type of
procedure; duration of surgery; operative blood loss; all peri- and
postoperative complications; readmission (within 30 days of dis-
charge); mortality (in hospital/within 30 days of surgery); post-
operative hospital LoS before being deemed medically fit for
discharge (Table 2), and LoS before actual discharge.
Major surgical complications were defined as:
• pancreatic fistula (PF): a drain output of any measurable
volume of fluid on or after PoD 3 with an amylase content
greater than three times the serum amylase level [according to
the International Study Group on Pancreatic Fistula (ISGPF)];40
• intra-abdominal abscess: a collection of fluid >5 cm in diameter
on computed tomography or ultrasound (ISGPF definition),40
• intra-abdominal haemorrhage defined according to the guide-
lines established by the International Study Group of Pancreatic
Surgery (ISGPS).41
Minor surgical complications were defined as:
• delayed gastric emptying (DGE) as indicated by an NGT that
remained in situ or was re-inserted after PoD 3 (ISGPS
definition).42
Results
Demographics
Fifty patients were eligible for this study and underwent PD fol-
lowing the introduction of an ERAS protocol. Demographic and
operative data are illustrated in Table 3.
Implementation of the ERAS protocol
Forty-three patients (86%) were commenced on epidural analge-
sia. In seven patients the epidural placement was unsuccessful or
functioned poorly, and PCA was utilized instead (Table 4). The
epidural was discontinued by PoD 3 in 42 patients; although in
one patient with a prolonged prothrombin time, the epidural
catheter remained in situ until PoD 4. In one patient, the epidural
was not stopped until PoD 6 for reasons of opioid tolerance. Only
23 of 48 transurethral urinary catheters were removed by PoD 3.
The median duration of urinary catheterization was 4 days [inter-
quartile range (IQR): 3–5 days] and two patients were given long-
term catheters.
The NGT was removed on PoD 1 in 39 patients (78%) and in all
patients by PoD 3. Patients in whom the NGT was not removed on
PoD 1 had either failed to meet NGT removal criteria or were
submitted to re-laparotomy. The NGT was re-inserted in seven
patients (14%) because of persistent nausea and vomiting. Oral
intake of clear fluids resumed by PoD 1 in 41 patients (82%) and
oral solid diet was tolerated by PoD 4 in 43 patients (86%). First
flatus and stool were passed at a median of PoD 4 (IQR: 3–5 days)
and PoD 6 (IQR: 4–7 days), respectively. In 25 patients (50%), i.v.
fluid support was discontinued by PoD 4, but this rose to 36
patients (72%) by PoD 5. Drain amylase was measured on PoD 5
in 45 patients (90%), on PoD 4 in three patients (6%) and on PoD
2 in one patient (2%). In one patient, no sample was sent. Drain
removal was delayed in 14 patients (28%). Delays were most often
caused by delays in obtaining fluid amylase results from the labo-
ratory; this was especially true if PoD 5 fell at the weekend as the
laboratory did not run the test during this time. Other reasons
included a change in the consistency of drain fluid and clinical
factors.
Only 18 patients (36%) achieved the target of mobilization on
PoD 0, although 42 patients (84%) did so on PoD 1. Poor com-
pliance reflected the fact that patients were clinically unfit (e.g.
hypotensive), sedated or in pain. Forty-one patients (82%) were
discharged from the HDU by PoD 3.
Postoperative outcomes
The overall in-hospital mortality rate was 4% (two patients), the
morbidity rate was 46% (23 patients) and the readmission rate
was 4% (Table 5).
The first death occurred in a 68-year-old woman who had
presented with jaundice and had undergone an extended PD to
include a pancreatic cyst without prior biliary decompression. She
developed an anastomotic leak and sepsis 8 days postoperatively
and underwent re-laparotomy. Subsequently, she developed a
colocutaneous fistula and progressive organ failure and died
121 days post-PD. The second patient was a 53-year-old man
who made an excellent initial recovery and was discharged on
PoD 7. He was readmitted on PoD 15 with an intra-abdominal
Table 3 Patient demographics and operative details
Categorical variable ERAS patients,
n = 50
Age, years, median (IQR) 67 (55–73)
Gender, male, n (%) 24 (48%)
Indication for PD, n (%)a
Head of pancreas carcinoma 26 (52%)
Ampullary carcinoma 16 (32%)
Distal CBD carcinoma 3 (6%)
Endocrine neoplasm 1 (2%)
Chronic pancreatitis 0
Other 4 (8%)
Procedure, n (%)
Classical PD 42 (84%)
Pylorus-preserving PD 6 (12%)
PD with SMV or portal vein resection 2 (4%)
Duration of surgery, min, median (IQR)a 360 (310–420)
Estimated theatre blood loss, ml, median (IQR)a 1000 (604–1275)
aData available for 48 patients.
ERAS, enhanced recovery after surgery; IQR, interquartile range; PD,
pancreaticoduodenectomy; CBD, common bile duct; SMV, superior
mesenteric vein.
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haemorrhage and underwent re-laparotomy. He suffered a fatal
cardiac arrest postoperatively. Three other patients underwent
re-laparotomy; in all patients the indication for re-laparotomy was
severe, late (>24 h), intra-abdominal haemorrhage. Postoperative
PF (POPF) occurred in six patients: one suffered Grade A POPF;
four patients had Grade B POPF, and one patient had Grade C
POPF. Delayed gastric emptying was the most common compli-
cation, occurring in seven patients (14%).
The median LoS for all ERAS patients was 10 days (IQR: 8–17
days). In patients without complications, the median LoS was 9
days (IQR: 8–10 days).
Hospital discharge was delayed for social or transport-related
reasons in 16 patients (32%) who were considered medically fit for
discharge. Discharge was delayed by 1–4 days in 14 of these
patients and by 10 days in two patients.
Discussion
Initial results from this pilot study show the feasibility and safety
of implementing an ERAS programme following PD. Mortality,
morbidity and readmission rates were low. A median LoS of 10
days was in keeping with LoS data reported in other PD fast-
track studies.19,36 Most of the targets were met by the majority
of patients: the NGT was successfully removed on PoD 1; oral
fluids and solid food were tolerated by PoD 1 and PoD 4,
respectively; epidural analgesia was initiated on PoD 0 and with-
drawn on PoD 3; abdominal drains were removed once criteria
were met, and patients were discharged from the HDU by PoD 3.
However, achieving compliance on several other targets was more
challenging.
Urinary catheter removal by PoD 3 was problematic as some
patients required ongoing monitoring of urine output, which was
easier to assess with the catheter in situ. Although this may sim-
plify the task for busy ward nurses, prolonged catheterization
increases the risk for infection and decreases patient mobility.
Similarly, i.v. fluid support could not be discontinued by PoD 4
in a number of patients in whom oral fluid intake was insufficient.
Patients may require more encouragement to take fluids orally.
Another challenge concerned the removal of intra-abdominal
drains. Although for the most part drain samples were sent for
fluid amylase analysis on PoD 5, it commonly took at least 1 day
more for the results to become available. If PoD 5 fell at the
weekend, the ensuing delays resulted in postponed drain removal.
A randomized controlled trial found significantly decreased rates
of PF, abdominal and pulmonary complications with early drain
removal (PoD 3) compared with late drain removal (PoD 5 and
later) in patients at low risk for PF (amylase values of <5000 U/l
on PoD 3).43 There is still debate on whether or not drains should
be routinely placed following PD and their use is based on low-
level evidence.44 A revised ERAS protocol should perhaps include
earlier analysis of drain fluid amylase with the target of achieving
earlier drain removal.
The protocol was also limited by insufficient patient compli-
ance with the mobilization programme. With hindsight, it is con-
ceivable that setting a target of ‘getting the patient up to sit’ on
PoD 0 was slightly idealistic because many patients were sedated
postoperatively or were clinically unfit or in pain. By PoD 1,
compliance had improved considerably; however, further prob-
lems arose at PoD 4, when patients were required to ‘walk for
Table 4 Implementation of enhanced recovery after surgery (ERAS)
programme protocol: key targets
ERAS postoperative targets Proportion of
patients achieving
key protocol
targets
NGT removal on PoD 1 39 of 50 (78%)
Resumption of oral fluids PoD 1 41 of 50 (82%)
Tolerating solid diet PoD 4 43 of 50 (86%)
i.v. fluid support stopped PoD 4 25 of 50 (50%)
i.v. fluid support stopped PoD 5 36 of 50 (72%)
Epidural analgesia PoD 0 43 of 50 (86%)
Epidural analgesia stopped PoD 3 42 of 43
Urinary catheter removal PoD 3 23 of 48a
Daily mobilization programme PoD 0 18 of 50 (36%)
Daily mobilization programme PoD 1 42 of 50 (84%)
Drain removal once criteria met 36 of 50 (72%)
HDU discharge PoD 3 41 of 50 (82%)
Discharge from hospital PoD 6 1 of 50 (2%)
Discharge from hospital PoD 7 8 of 50 (16%)
Discharge from hospital PoD 8 15 of 50 (30%)
Discharge from hospital PoD 9 18 of 50 (36%)
Discharge from hospital PoD 10 26 of 50 (52%)
aTwo patients had longterm urinary catheters.
NGT, nasogastric tube; PoD, postoperative day; HDU, high-dependency
unit.
Table 5 Postoperative course in the enhanced recovery after surgery
(ERAS) programme
ERAS patients,
n = 50
Postoperative LoS, days, median (IQR)
All patients 10 (8–17)
Patients without complications 9 (8–10)
Postoperative morbidity, n (%) 23 (46%)
Postoperative pancreatic fistula, n (%) 6 (12%)
Delayed gastric emptying, n (%) 7 (14%)
Intra-abdominal collection, n (%) 5 (10%)
Intra-abdominal haemorrhage, n (%) 4 (8%)
Re-laparotomy, n (%) 5 (10%)
Readmission, n (%) 2 (4%)
Postoperative mortality, n (%) 2 (4%)
LoS, length of stay; IQR, interquartile range.
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20 min’ in order to achieve the mobilization target. Able-bodied,
de-catheterized patients were able to achieve this, but several
patients required intense nursing or physiotherapist input to
achieve this goal and staffing and time constraints can prevent this
from occurring.
Other minor issues pertaining to the clinical communication of
daily targets were noted. On at least one occasion, a patient who
might have tolerated solid diet by PoD 4 was refused diet because
he or she was documented as being restricted to free oral fluids
only.
Following this study, an aspect of the protocol that may require
revision concerns the use of postoperative NGTs. Although this
has not been explored exclusively in pancreatic surgery, evidence
suggests that the routine use of NGTs following elective laparo-
tomy is not warranted.45,46
A further component of this ERAS protocol was that solid food
was withheld until PoD 4. There is a lack of evidence to support
this and early diet has been shown to be safe following major
upper GI and HPB surgery, including PD.47 A revised ERAS pro-
tocol may forgo the imposition of formal restrictions on postop-
erative diet in an attempt to improve upper GI function.
A study comparing epidural with i.v. analgesia post-PD sug-
gested that thoracic analgesia is associated with a higher rate of
complications as a result of haemodynamic instability.48 It is pos-
sible that haemodynamic instability may have compromised
mobility and urinary catheter removal in this study through issues
of hypotension and fluid management. However, there is abun-
dant evidence to support epidural analgesia as a very effective
form of analgesia following major abdominal surgery.49–53
Personal preoperative counselling targeting patient expecta-
tions is key to enhanced recovery: it helps to alleviate fear and
anxiety, and explains the importance of achieving daily targets.54–56
Although the protocol was implemented in a ward familiar with
ERAS programmes for liver resection patients, ERAS for patients
following PD was a new phenomenon. Patients were counselled
preoperatively with regard to postoperative recovery, but this
could be enhanced further with additional personal counselling
and the provision of specialist nurse support.
In retrospect, the target of discharge from hospital on PoD 6
was ambitious. The earliest median discharge reported in the lit-
erature was 7 days in a US study, but this has only been reported
once.18 The majority of patients (52%) in this study were dis-
charged by PoD 10, although, interestingly, nearly one third of
patients were subject to delayed discharge for social or transport-
related reasons. Previous studies have reported that postoperative
LoS is reduced in patients on ERAS programmes compared with
historical controls.20,34,35 The median LoS following the introduc-
tion of ERAS in this series is notably shorter than the 13 days
reported in a historical series of 449 patients in this institution
(R.W. Parks, University of Edinburgh, unpublished results). A
postoperative stay of 10 days is also shorter than those reported
in most published studies.34,35 In a future ERAS protocol, a target
of hospital discharge on PoD 9 may be a more realistic goal in a
UK health care setting as this was the median LoS for patients
without complications in this study.
The reductions in LoS seen in ERAS studies for PD do not
compare with the impressive reductions reported in ERAS studies
for colorectal or liver resections. It could be argued that this
reflects the high rate of morbidity following PD (30–40%) relative
to the acknowledged lower rate of complications following colo-
rectal and standard liver resections. A lower morbidity rate means
that recovery in the majority of patients will be influenced only by
gut function, pain and mobility (other than social or transport-
related issues). However, in PD a smaller proportion of patients
fall into this category and even they face more troublesome gut
motility problems. Therefore, there is less scope to improve recov-
ery by enhancing gut function, reducing pain and improving
mobility because the high morbidity rate will overshadow any
gain in functional capacity.
The postoperative morbidity rate in this series is in keeping
with the results of the majority of studies.20,35–37 Without a control
group, the current study cannot demonstrate a significant reduc-
tion in morbidity. One study reported a reduced rate of DGE in
fast-track patients.34
In conclusion, initial results from this study show the feasibility
and safety of implementing an ERAS programme following PD.
Most targets were met, although some proved more challenging,
particularly those relating to early mobilization and the removal
of urinary catheters and abdominal drains. There were several
reasons for this, including: staffing levels and time constraints; the
need to monitor urine output in a proportion of patients, and
delays in obtaining drain amylase results from the laboratory.
Further modification of the protocol and additional education of
patients and health professionals may help to improve recovery,
shorten hospital stay and enhance the return of normal function.
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